Dimerix Limited (DXB.AX)

0.3600 +0.0250 (+7.46%) At close: 04:10PM AEST

Dimerix Limited

425 Smith Street
Fitzroy, VIC 3065
Australia
1300 813 321
https://dimerix.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, MBA, Ph.D.	CEO, MD & Director	386.82k	N/A	N/A
Mr. Hamish George B.Com., C.A.	CFO & Company Secretary	N/A	N/A	N/A
Dr. David Everett Fuller BPharm, M.D., MBBS	Chief Medical Officer	N/A	N/A	1964
Mr. Kevin Donald George Pfleger BA (Hons), MA, Ph.D.	Chief Scientific Advisor	N/A	N/A	N/A
Mr. Robert Shepherd	Chief Commercialisation Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. The company is headquartered in Fitzroy, Australia.

Corporate governance

Dimerix Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.